Progress with RNA Interference for the Treatment of Primary Hyperoxaluria

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Primary hyperoxaluria (PH) is an autosomal recessive disorder caused by mutations in genes regulating endogenous oxalate synthesis.
• Severe PH can lead to kidney failure and systemic oxalosis, with limited treatment options historically available.
• N-acetyl galactosamine conjugation facilitates liver-specific delivery of RNA interference therapeutics, minimizing off-target effects.

Purpose of the Study:

• To review the development and application of RNA interference (RNAi) therapies for primary hyperoxaluria type 1 (PH1).
• To discuss the mechanism of action and clinical outcomes of approved and investigational RNAi drugs targeting PH1.
• To evaluate the potential impact of these novel therapies on the natural history of PH1.

Main Methods:

• Review of recent US Food and Drug Administration approvals for RNA interference drugs.
• Analysis of drug development targeting specific genes in oxalate synthesis pathways (GO, LDH-A).
• Examination of clinical data and therapeutic potential for PH1, PH2, and PH3.

Main Results:

• Lumasiran, targeting glycolate oxidase (GO), is approved for PH1 treatment.
• Nedosiran, targeting lactate dehydrogenase A (LDH-A), is under regulatory review for PH1.
• Current data suggest nedosiran may not be effective for PH2 or PH3.

Conclusions:

• RNA interference therapies represent a significant advancement in treating primary hyperoxaluria type 1.
• Liver-specific targeting with N-acetyl galactosamine conjugation enhances drug efficacy and safety.
• These novel treatments are poised to alter the disease course for PH1 patients.